|
1
|
Vatanasapt V, Sriamporn S and Vatanasapt
P: Cancer control in Thailand. Jpn J Clin Oncol. 32:(Suppl).
S82–S91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Endo I, Gonen M, Yopp AC, Dalal KM, Zhou
Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, et
al: Intrahepatic cholangiocarcinoma: Rising frequency, improved
survival, and determinants of outcome after resection. Ann Surg.
248:84–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sripa B and Pairojkul C:
Cholangiocarcinoma: Lessons from Thailand. Curr Opin Gastroenterol.
24:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wongkham S and Silsirivanit A: State of
serum markers for detection of cholangiocarcinoma. Asian Pac J
Cancer Prev. 13:(Suppl). S17–S27. 2012.
|
|
5
|
Anderson CD, Pinson CW, Berlin J and Chari
RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist.
9:43–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adams WJ and Morris DL: Short-course
cimetidine and survival with colorectal cancer. Lancet.
344:1768–1769. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Freston JW: Cimetidine: II. Adverse
reactions and patterns of use. Ann Intern Med. 97:728–734. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tønnesen H, Knigge U, Bülow S, Damm P,
Fischerman K, Hesselfeldt P, Hjortrup A, Pedersen IK, Pedersen VM
and Siemssen OJ: Effect of cimetidine on survival after gastric
cancer. Lancet. 2:990–992. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adams W and Morris D: Cimetidine and
colorectal cancer. Dis Colon Rectum. 39:111–112. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kelly MD, King J, Cherian M, Dwerryhouse
SJ, Finlay IG, Adams WJ, King DW, Lubowski DZ and Morris DL:
Randomized trial of preoperative cimetidine in patients with
colorectal carcinoma with quantitative assessment of
tumor-associated lymphocytes. Cancer. 85:1658–1663. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dexeus FH, Logothetis CJ, Sella A, Fitz K,
Amato R, Reuben JM and Dozier N: Phase II study of coumarin and
cimetidine in patients with metastatic renal cell carcinoma. J Clin
Oncol. 8:325–329. 1990.PubMed/NCBI
|
|
12
|
Morton RF, Creagan ET, Cullinan SA,
Mailliard JA, Ebbert L, Veeder MH and Chang M: Phase II studies of
single-agent cimetidine and the combination
N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine
(NSC-153353) in advanced malignant melanoma. J Clin Oncol.
5:1078–1082. 1987.PubMed/NCBI
|
|
13
|
Lefranc F, Yeaton P, Brotchi J and Kiss R:
Cimetidine, an unexpected anti-tumor agent, and its potential for
the treatment of glioblastoma (review). Int J Oncol. 28:1021–1030.
2006.PubMed/NCBI
|
|
14
|
Adams WJ, Lawson JA and Morris DL:
Cimetidine inhibits in vivo growth of human colon cancer and
reverses histamine stimulated in vitro and in vivo growth. Gut.
35:1632–1636. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Natori T, Sata M, Nagai R and Makuuchi M:
Cimetidine inhibits angiogenesis and suppresses tumor growth.
Biomed Pharmacother. 59:56–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sahasrabudhe DM, McCune CS, O'Donnell RW
and Henshaw EC: Inhibition of suppressor T lymphocytes (Ts) by
cimetidine. J Immunol. 138:2760–2763. 1987.PubMed/NCBI
|
|
17
|
Kobayashi K, Matsumoto S, Morishima T,
Kawabe T and Okamoto T: Cimetidine inhibits cancer cell adhesion to
endothelial cells and prevents metastasis by blocking E-selectin
expression. Cancer Res. 60:3978–3984. 2000.PubMed/NCBI
|
|
18
|
Seubwai W, Vaeteewoottacharn K, Hiyoshi M,
Suzu S, Puapairoj A, Wongkham C, Okada S and Wongkham S:
Cepharanthine exerts antitumor activity on cholangiocarcinoma by
inhibiting NF-kappaB. Cancer Sci. 101:1590–1595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ono A, Hattori S, Kariya R, Iwanaga S,
Taura M, Harada H, Suzu S and Okada S: Comparative study of human
hematopoietic cell engraftment into BALB/c and C57BL/6 strain of
rag-2/jak3 double-deficient mice. J Biomed Biotechnol.
2011:5397482011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kubecova M, Kolostova K, Pinterova D,
Kacprzak G and Bobek V: Cimetidine: An anticancer drug? Eur J Pharm
Sci. 42:439–444. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morris DL and Adams WJ: Cimetidine and
colorectal cancer-old drug, new use? Nat Med. 1:1243–1244. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vaeteewoottacharn K, Seubwai W,
Bhudhisawasdi V, Okada S and Wongkham S: Potential targeted therapy
for liver fluke associated cholangiocarcinoma. J Hepatobiliary
Pancreat Sci. 21:362–370. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maemura K, Natsugoe S and Takao S:
Molecular mechanism of cholangiocarcinoma carcinogenesis. J
Hepatobiliary Pancreat Sci. 21:754–760. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmitz KJ, Lang H, Wohlschlaeger J,
Sotiropoulos GC, Reis H, Schmid KW and Baba HA: AKT and ERK1/2
signaling in intrahepatic cholangiocarcinoma. World J
Gastroenterol. 13:6470–6477. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Adams WJ, Morris DL, Ross WB, Lubowski DZ,
King DW and Peters L: Cimetidine preserves non-specific immune
function after colonic resection for cancer. Aust N Z J Surg.
64:847–852. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng Y, Xu M, Li X, Jia J, Fan K and Lai
G: Cimetidine suppresses lung tumor growth in mice through
proapoptosis of myeloid-derived suppressor cells. Mol Immunol.
54:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
